Pentasaccharides for the prevention of venous thromboembolism

Abstract

Analysis 2.3. Comparison 2 Fondaparinux versus placebo sensitivity analysis inserting Yokote 2011, Outcome 3 total DVT......... Analysis 2.4. Comparison 2 Fondaparinux versus placebo sensitivity analysis inserting Yokote 2011, Outcome 4 proximal DVT..... Analysis 2.5. Comparison 2 Fondaparinux versus placebo sensitivity analysis inserting Yokote 2011, Outcome 5 total PE........... Analysis 2.6. Comparison 2 Fondaparinux versus placebo sensitivity analysis inserting Yokote 2011, Outcome 6 fatal PE........... Analysis 2.7. Comparison 2 Fondaparinux versus placebo sensitivity analysis inserting Yokote 2011, Outcome 7 non-fatal PE...... Analysis 2.8. Comparison 2 Fondaparinux versus placebo sensitivity analysis inserting Yokote 2011, Outcome 8 major bleeding.

Pharmacotherapy for Venous Thromboprophylaxis following Total Hip or Knee Arthroplasty: A Systematic Review and Network Meta-analysis

“…While pentasaccharides are an exception, this is consistent with prior studies. 121 These results support the use of factor Xa inhibitors in reducing VTE post-arthroplasty. In addition, whereas LMWH requires parenteral administra-tion, factor Xa inhibitors can be administered orally, which may be more comfortable for patients and facilitate adherence to outpatient extended thromboprophylaxis.…”

Pharmacotherapy for Venous Thromboprophylaxis following Total Hip or Knee Arthroplasty: A Systematic Review and Network Meta-analysis

“…While pentasaccharides are an exception, this is consistent with prior studies. 121 These results support the use of factor Xa inhibitors in reducing VTE post-arthroplasty. In addition, whereas LMWH requires parenteral administra-tion, factor Xa inhibitors can be administered orally, which may be more comfortable for patients and facilitate adherence to outpatient extended thromboprophylaxis.…”

Unlocking the potential of fondaparinux: guideline for optimal usage and clinical suggestions (2023)

“…A systematic meta-analysis of the use of fondaparinux and LMWH for perioperative thromboprophylaxis for VTE ( Kumar et al, 2019 ) revealed that the incidence of VTE events was greater in the LMWH group than in the fondaparinux group up to 15 days postsurgery, and the probability of total DVT was 0.48-fold greater in the fondaparinux group than in the LMWH group; however, the incidence of major bleeding events was greater in the fondaparinux group than in the LMWH group. Another review mentioned that fondaparinux may be more effective than LMWH in preventing VTE, but it increases the incidence of major bleeding ( Dong et al, 2016 ).…”

Consenso de tromboprofilaxis en cirugía ginecológica

“…Una revisión sistemática de la literatura 6 (AM-STAR 2: confianza moderada) evaluó la seguridad y la efectividad del uso de fondaparina para el manejo de los pacientes con cirugía mayor. La intervención consistió en el inicio de fondaparina durante los 7 días previos a la intervención hasta 45 días luego del procedimiento quirúrgico.…”

Pharmacotherapy for Venous Thromboprophylaxis following Total Hip or Knee Arthroplasty: A Systematic Review and Network Meta-analysis

“…While pentasaccharides are an exception, this is consistent with prior studies. 121 These results support the use of factor Xa inhibitors in reducing VTE post-arthroplasty. In addition, whereas LMWH requires parenteral administra-tion, factor Xa inhibitors can be administered orally, which may be more comfortable for patients and facilitate adherence to outpatient extended thromboprophylaxis.…”

Unlocking the potential of fondaparinux: guideline for optimal usage and clinical suggestions (2023)

“…A systematic meta-analysis of the use of fondaparinux and LMWH for perioperative thromboprophylaxis for VTE ( Kumar et al, 2019 ) revealed that the incidence of VTE events was greater in the LMWH group than in the fondaparinux group up to 15 days postsurgery, and the probability of total DVT was 0.48-fold greater in the fondaparinux group than in the LMWH group; however, the incidence of major bleeding events was greater in the fondaparinux group than in the LMWH group. Another review mentioned that fondaparinux may be more effective than LMWH in preventing VTE, but it increases the incidence of major bleeding ( Dong et al, 2016 ).…”

Consenso de tromboprofilaxis en cirugía ginecológica

“…Una revisión sistemática de la literatura 6 (AM-STAR 2: confianza moderada) evaluó la seguridad y la efectividad del uso de fondaparina para el manejo de los pacientes con cirugía mayor. La intervención consistió en el inicio de fondaparina durante los 7 días previos a la intervención hasta 45 días luego del procedimiento quirúrgico.…”

Pharmacotherapy for Venous Thromboprophylaxis following Total Hip or Knee Arthroplasty: A Systematic Review and Network Meta-analysis

“…While pentasaccharides are an exception, this is consistent with prior studies. 121 These results support the use of factor Xa inhibitors in reducing VTE post-arthroplasty. In addition, whereas LMWH requires parenteral administra-tion, factor Xa inhibitors can be administered orally, which may be more comfortable for patients and facilitate adherence to outpatient extended thromboprophylaxis.…”

Unlocking the potential of fondaparinux: guideline for optimal usage and clinical suggestions (2023)

“…A systematic meta-analysis of the use of fondaparinux and LMWH for perioperative thromboprophylaxis for VTE ( Kumar et al, 2019 ) revealed that the incidence of VTE events was greater in the LMWH group than in the fondaparinux group up to 15 days postsurgery, and the probability of total DVT was 0.48-fold greater in the fondaparinux group than in the LMWH group; however, the incidence of major bleeding events was greater in the fondaparinux group than in the LMWH group. Another review mentioned that fondaparinux may be more effective than LMWH in preventing VTE, but it increases the incidence of major bleeding ( Dong et al, 2016 ).…”

Consenso de tromboprofilaxis en cirugía ginecológica

“…Una revisión sistemática de la literatura 6 (AM-STAR 2: confianza moderada) evaluó la seguridad y la efectividad del uso de fondaparina para el manejo de los pacientes con cirugía mayor. La intervención consistió en el inicio de fondaparina durante los 7 días previos a la intervención hasta 45 días luego del procedimiento quirúrgico.…”